Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Physiologic versus malignant uncinate process uptake on 68Ga-DOTA-TATE PET/MRI

C Elias Graybiel and Thomas Hope
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 565;
C Elias Graybiel
2Department of Radiology and Biomedical Imaging University of California San Francisco (UCSF) San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Hope
1University of California San Francisco San Francisco CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

565

Introduction: Radiotracer uptake in the uncinate process is a frequent normal finding at somatostatin receptor PET imaging. In patients with neuroendocrine tumors, however, this physiologic activity can occasionally be difficult to distinguish from pancreatic masses, proximal small bowel tumors, or nodal metastases, and requires careful evaluation of CT or MR images to confirm the absence of an associated structural abnormality. PET and MRI data can be obtained concurrently with PET/MRI, which allows for optimal co-localization of abnormalities detected on either or both modalities. Materials and Methods: We evaluated for the presence or absence of uncinate process uptake on 68Ga-DOTA-TATE PET/MRIs in 86 patients with known or suspected primary neuroendocrine tumors and characterized the uptake as either focal or diffuse. In cases where uncinate process uptake was present, T1 pre-contrast, T2, diffusion-weighted, and post-contrast MR images were reviewed to assess for underlying structural lesions as a cause for the uptake, and SUVmax was obtained from the PET images.

Results: Uncinate process activity was present in 39 of 86 cases (45%) and absent in the remaining 47 cases. In the 39 patients with uncinate process uptake, 28 had diffuse uptake and 11 had focal uptake. All cases (28) of diffuse uncinate uptake were without restricted diffusion or other MR abnormality and deemed physiologic. Nine out of 11 cases (82%) with focal uptake demonstrated an associated pathologic lesion with restricted diffusion or other MR abnormality, while the remaining 2 were physiologic. Radiotracer uptake in cases with physiologic uncinate activity had lower SUVmax (10.5+/-7.2) when compared to cases of malignant disease (SUVmax 63.2+/-52.0)(p < 0.001).

Conclusions: Physiologic uncinate process uptake is commonly found in patients undergoing somatostatin receptor PET imaging. More than one-third of our patients had physiologic uncinate activity at 68Ga-DOTA-TATE PET/MRI. Although there is some overlap, SUVmax values appear to be valuable in determining whether uptake in the uncinate process is physiologic, and features such as a diffuse pattern of uptake and absence of a DWI abnormality can improve interpretive confidence.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Physiologic versus malignant uncinate process uptake on 68Ga-DOTA-TATE PET/MRI
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Physiologic versus malignant uncinate process uptake on 68Ga-DOTA-TATE PET/MRI
C Elias Graybiel, Thomas Hope
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 565;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Physiologic versus malignant uncinate process uptake on 68Ga-DOTA-TATE PET/MRI
C Elias Graybiel, Thomas Hope
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 565;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • Preliminary Clinical Results for 18F-FDGPET/MR Compared with PET/CT in Patients with Suspected Recurrent or Metastatic Differentiated Thyroid Cancer
  • Clinical value of 99mTc-deoxy-glucose derivative SPECT/CT in tumors
Show more Oncology: Clinical Therapy and Diagnosis

Therapy Concepts I: Endocrinology

  • Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Progressive Grade 3 Neuroendocrine Neoplasms (NEN)
  • Possibility of 123I-meta-iodobenzylguanidine (123I-MIBG) as companion diagnostic drug for therapeutic alpha-emitting meta-211At-astato-benzylguanidine (211At-MABG)
  • Evaluation of the CCK-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - Final Results of the phase 0 "Lumed" Study.
Show more Therapy Concepts I: Endocrinology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire